OncoMatch/Clinical Trials/NCT06342986
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Is NCT06342986 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including FT536 and Fludarabine for gynecologic cancer.
Treatment: FT536 · Fludarabine · CY — This is a single center Phase I clinical trial of FT536 administered intraperitoneally (IP) 3 times a week for one week for the treatment of recurrent gynecologic cancers. A short course of outpatient lymphodepleting chemotherapy is given prior to the first dose of FT536 to promote adoptive transfer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Allowed: BRCA1 mutation
Allowed: BRCA2 mutation
Prior therapy
Must have received: bevacizumab (bevacizumab)
Must have received prior bevacizumab.
Must have received: PARP inhibitor
In the presence of a BRCA mutation, must have received a prior PARP inhibitor.
Cannot have received: enoblituzumab (enoblituzumab)
Prior enoblituzumab.
Cannot have received: biological therapy
Exception: except palliative RT
Receipt of any biological therapy, chemotherapy, or radiation therapy (except palliative RT), within 2 weeks prior to the first dose of FT536 or five half-lives, whichever is shorter; or any investigational agent within 28 days prior to the first dose of FT536.
Cannot have received: chemotherapy
Exception: except palliative RT
Receipt of any biological therapy, chemotherapy, or radiation therapy (except palliative RT), within 2 weeks prior to the first dose of FT536 or five half-lives, whichever is shorter; or any investigational agent within 28 days prior to the first dose of FT536.
Cannot have received: radiation therapy
Exception: except palliative RT
Receipt of any biological therapy, chemotherapy, or radiation therapy (except palliative RT), within 2 weeks prior to the first dose of FT536 or five half-lives, whichever is shorter; or any investigational agent within 28 days prior to the first dose of FT536.
Cannot have received: investigational agent
any investigational agent within 28 days prior to the first dose of FT536.
Lab requirements
Blood counts
Adequate organ function within 14 days (28 days for pulmonary and cardiac) of study treatment (CY/Flu) start
Kidney function
Adequate organ function within 14 days (28 days for pulmonary and cardiac) of study treatment (CY/Flu) start
Liver function
Adequate organ function within 14 days (28 days for pulmonary and cardiac) of study treatment (CY/Flu) start
Cardiac function
Adequate organ function within 28 days of study treatment (CY/Flu) start
Adequate organ function within 14 days (28 days for pulmonary and cardiac) of study treatment (CY/Flu) start
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Minnesota Masonic Cancer Center · Minneapolis, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify